Tom Samuelson, MBA
Mr. Samuelson is a member of Triple-Gene’s Board of Directors. He is also a Vice President at Precigen*, focusing on the intersection of finance and operations. His primary responsibilities include mergers/divestitures, capital allocation, financial planning/analysis, and business development across Precigen’s health verticals. Mr. Samuelson sits on the board of a number of Precigen subsidiaries and joint ventures. He joined Precigen from the healthcare investment banking group at JP Morgan where he covered specialty gene and cell therapies. He is a graduate of Williams College and MIT.
(*Intrexon Corporation announced it will change its name to Precigen, Inc.)
While members of the Medical Advisory Board are consulted to provide third party expert medical input into Triple-Gene’s product development efforts and clinical trial activities, they do not dictate or direct, nor are they responsible for, any development or clinical activities ultimately undertaken by Triple-Gene.